0000000000955722

AUTHOR

N. Scichilone

showing 20 related works from this author

Is mild asthma in real life always in the Green Zone?

2014

Asthma is a chronic inflammatory disease of the airways that is characterized by variable narrowing of the airways and symptoms of intermittent dyspnea, wheezing, and nighttime or early-morning coughing. Asthma is a major health problem throughout the world, affecting an estimated 315 million persons of all ages. Asthma is clinically heterogeneous, and its pathophysiology is complex. For convenience, asthma action plans are often broken down into three zones, usually based on peak flow meter recordings: green, yellow, and red according to the level of lung function impairment. Recent evidence shows that every asthmatic is potentially at risk for severe exacerbation independently of his/her …

asthma control lung function exacerbationSettore MED/10 - Malattie Dell'Apparato Respiratorio
researchProduct

Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA-ARIA-EPOS-AIRWAYS IC…

2017

Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions. The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging dat…

allergic rhinitis; integrated care pathway; precision medicine; rhinosinusitisAllergyRhinosinusitisDiseaseAllergic rhinitis0302 clinical medicineQUALITY-OF-LIFEMedicineImmunology and Allergy030223 otorhinolaryngologySinusitisNASAL POLYPOSISRhinitisPrecision medicineintegrated care pathway3. Good healthAlgorithmREAL-LIFEIMPACT OUTCOMESARIA and EPOS working groups1107 ImmunologyDISEASESGA(2)LENDisease Progressionallergic rhinitiLife Sciences & BiomedicineENDOSCOPIC SINUS SURGERYAlgorithmsHumanIntegrated care pathwayallergic rhinitis; integrated care pathway; precision medicine; rhinosinusitis; Adult; Algorithms; Chronic Disease; Disease Progression; Humans; Precision Medicine; Rhinitis Allergic; Sinusitis; Young Adult; Immunology and Allergy; ImmunologyAdultmedicine.medical_specialtyprecision medicineImmunologyrhinosinusitiPHENOTYPESVALIDATIONYoung Adult03 medical and health sciencesTherapeutic approachAllergicPatient satisfactionQuality of life (healthcare)HumansSinusitisPatient participationIMMUNOTHERAPYIntensive care medicinerhinosinusitisAsthmaScience & Technologyallergic rhinitis; integrated care pathway; precision medicine; rhinosinusitis; Immunology and Allergy; Immunologyallergic rhinitisbusiness.industrymedicine.diseasePrecision medicineSinusitiRhinitis AllergicSEVERITY030228 respiratory system3121 General medicine internal medicine and other clinical medicineChronic DiseasePhysical therapyASTHMAbusiness
researchProduct

Effects of omalizumab in severe asthmatics across ages: A real life Italian experience

2016

Background This retrospective study aimed at evaluating long-term effects of Omalizumab in elderly asthmatics in a real-life setting. Methods 105 consecutive severe asthmatics (GINA step 4–5; mean FEV1% predicted:66 ± 15.7) treated with Omalizumab for at least 1 year (treatment mean duration 35.1 ± 21.7 months) were divided into 3 groups according to their age at Omalizumab treatment onset: 18–39, 40–64 and ≥ 65 years. Results Comorbidities, number of overweight/obese subjects and patients with late-onset asthma were more frequent among older people. A similar reduction of inhaled corticosteroids dosage and SABA on-demand therapy was observed in all groups during Omalizumab treatment; a sim…

MaleSevere asthmaPediatricsComorbidityOmalizumabOmalizumabOverweightImmunoglobulin ESeverity of Illness IndexElderly0302 clinical medicineAdrenal Cortex HormonesForced Expiratory VolumeAge effectAnti-Asthmatic Agentsasthma allergy elderly omalizumab030212 general & internal medicineYoung adultbiologyReal-lifeAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeItalyFemalemedicine.symptommedicine.drugAdultPulmonary and Respiratory Medicineage effect; elderly; omalizumab; real-life; severe asthmamedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciencesAge effect; Elderly; Omalizumab; Real-life; Severe asthma; Pulmonary and Respiratory MedicineAdministration InhalationSeverity of illnessmedicineHumansAgedRetrospective StudiesAsthmabusiness.industryRetrospective cohort studyImmunoglobulin Easthmaallergymedicine.diseaseComorbidity030228 respiratory systembiology.proteinbusinessRespiratory Medicine
researchProduct

Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: A non-inferiority, randomised, double-blind clinical tr…

2015

Summary Background Treatment guidelines for patients with moderate persistent asthma recommend regular therapy with a combination of an inhaled corticosteroid and a longacting β 2 agonist plus as-needed rapid-acting bronchodilators. We investigated whether symptom-driven budesonide and formoterol combination therapy administered as needed would be as effective as regular treatment with this combination plus as-needed symptom-driven terbutaline for patients with moderate asthma. Methods In this non-inferiority randomised clinical trial, we recruited adult patients (18–65 years of age) with stable moderate persistent asthma, according to 2006 Global Initiative for Asthma guidelines. Patients …

BudesonideMalePediatricsKaplan-Meier Estimatelaw.inventionRandomized controlled triallawMedicineOutpatient clinicBudesonide Formoterol Fumarate Drug CombinationAnti-Asthmatic AgentsTreatment Failureeducation.field_of_studyasthma; clinical trialMedicine (all)clinical trialMiddle AgedCombined Modality TherapyBronchodilator AgentsFemalemedicine.drugHumanAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentTerbutalinePopulationSettore MED/10 - Malattie Dell'Apparato RespiratorioPlaceboDrug Administration ScheduleNOYoung AdultDouble-Blind MethodAdministration InhalationTerbutalineinhaled corticosteroids LABA asthma clinical trialHumansAnti-Asthmatic AgenteducationBronchodilator AgentPulmonary and Respiratory Medicine; Medicine (all)AsthmaAgedPulmonary and Respiratory Medicine RCT asthmabusiness.industryComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSmedicine.diseaseAsthmarespiratory tract diseasesFormoterolbusiness
researchProduct

COPD classification methods and informativeness on mortality: Contrasting evidences

2013

Understanding whether the ABCD GOLD classification method is informative with respect to the spirometric classification of severity in predicting mortality of patients with chronic obstructive pulmonary disease (COPD) is subject of debate. The results of a study performed on a sample of the Norwegian population (HUNT2) were recently published. Such data showed the inferiority of ABCD classification in predicting mortality compared to the spirometric classification, which was considered the gold standard up to the 2011 version of GOLD guidelines. This result is not in line with the results of other studies that have shown the equivalence of the two classifications. The new GOLD classificatio…

EpidemiologyCOPD guidelines lung functionPulmonary diseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioChronic obstructive-pulmonary diseaseLung diseasesChronic obstructive; Chronic obstructive-pulmonary disease; Epidemiology; Lung diseases; Pulmonary diseaseChronic obstructive
researchProduct

Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry

2020

Abstract Background The clinical and laboratory features of patients enrolled in the Severe Asthma Network in Italy (SANI) registry, a web-based observatory collecting demographic, clinical, functional and inflammatory data of patients with severe asthma were evaluated, with a special emphasis to chronic rhinosinusitis with nasal polyposis (CRSwNP). Methods For each eligible patients the following information has been collected: demographic data, clinical features, asthma control in the previous month according to the GINA (Global INitiative for Asthma) Guidelines and standardized questionnaires, concomitant regular and on demand treatments and inflammatory markers. Results 695 patients wit…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtySevere asthmaDatabases FactualAdministration OralComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideSeverity of Illness IndexComorbiditiesOral corticosteroidAdrenal Cortex HormonesInternal medicineSeverity of illnessOral corticosteroidsmedicinePrevalenceNasal polypsHumansNasal polypsRegistriesSinusitisSinusitisAsthmaAgedRhinitisInternetBronchiectasisbusiness.industryNasal polypSettore MED/09 - MEDICINA INTERNAAtopic dermatitisComorbidities; Nasal polyps; Oral corticosteroids; Severe asthmaMiddle Agedmedicine.diseaseComorbidityAsthmaComorbidities Nasal polyps Oral corticosteroids Severe asthmaItalyConcomitantChronic DiseaseDisease ProgressionFemaleComorbiditiebusiness
researchProduct

Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?

2021

severe asthma2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaImmunologyComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioCOVID-19 severe asthma COPDNOHumans; SARS-CoV-2; Asthma; COVID-19Internal medicineCorrespondencemedicineCOPDImmunology and AllergyHumansAsthmaCOVIDbusiness.industrySARS-CoV-2COVID-19asthmamedicine.diseaseItalybusiness
researchProduct

Adherence issues related to sublingual immunotherapy as perceived by allergists.

2010

Silvia Scurati1, Franco Frati1, Gianni Passalacqua2, Paola Puccinelli1, Cecile Hilaire1, Cristoforo Incorvaia3, Italian Study Group on SLIT Compliance 1Scientific and Medical Department, Stallergenes, Milan, Italy; 2Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa; 3Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyObjectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many European countries. The clinical efficacy of SLIT has been established in a number of clinical trials and meta-analyses. However, because SLIT is self-administered…

medicine.medical_specialtyPathologygenetic structuresefficacyAlternative medicineMedicine (miscellaneous)Adherence Cost Efficacy Side effects Sublingual immunotherapySettore MED/10 - Malattie Dell'Apparato Respiratoriosublingual immunotherapyALLERGENcostmedicineSubcutaneous immunotherapySublingual immunotherapyadherenceClinical efficacyIntensive care medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)sublingual immunoterapyOriginal ResearchAsthmaAEROALLERGENSadherence; sublingual immunotherapy; efficacy; cost; side effectsbusiness.industryHealth Policymedicine.diseaseSliteye diseasesClinical trialside effectsPatient Preference and Adherenceadherence; sublingual immunoterapy; efficacy; cost; side effects.immunotherapysense organsAllergistsADHERENCE TO TREATMENTbusinessSocial Sciences (miscellaneous)
researchProduct

Cypress pollen: An unexpected major sensitizing agent in different regions of Italy

2014

In this multicenter survey, we assessed the impact of sensitization to cypress in atopic patients in Italy and determined whether cypress pollen concentration changed over time.Allergists were required to collect the results of 100-200 consecutive skin prick tests (SPTs) performed during 2012. Seasonal symptoms were also recorded, as were airborne cypress pollen concentrations (data from the Italian Aerobiology Association) in 1998-2000 and 2010-2012.We examined 2258 atopic outpatients (56% females; age, 2-84 years) sensitized to at least 1 of the aeroallergens tested (Dermatophagoides species, grass, pellitory, olive, cypress, birch, Alternaria tenuis, and dog and cat dander). We found tha…

CupressuAdultHypersensitivity ImmediateMaleAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioSensitizationYoung AdultHypersensitivityHumansChildAgedAged 80 and overAllergenRespiratory allergy; Cypress; Sensitization; Skin prick tests; allergyCypressAllergensCupressusMiddle AgedRespiratory allergyallergyYoung Adult; Humans; Aged; Child; Pollen; Italy; Child Preschool; Hypersensitivity; Aged 80 and over; Allergens; Adult; Hypersensitivity Immediate; Middle Aged; Adolescent; Cupressus; Male; FemaleItalyChild PreschoolSkin prick testsPollenFemaleHuman
researchProduct

Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA

2016

The authors would like to change and use the correct name of M. Khaitov which is M. Kaitov on this manuscript. The authors have incorrectly used her other name during the finalization of this research. With this, the authors hereby publish the correct author names as presented above. © 2016 Serdi and Springer-Verlag France

Nutrition and DieteticsNutrition & DieteticsGeriatrics gerontologybusiness.industryMedicine (miscellaneous)Settore MED/10 - Malattie Dell'Apparato RespiratorioallergyFinalizationAsthmaAction (philosophy)Correct nameMedicineEngineering ethicsGeriatrics and GerontologybusinessQuality of Life Research
researchProduct

Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

2015

Few data are available on the proportion of asthmatics achieving a good asthma control (according GINA guidelines) and on the level of airway inflammation during omalizumab treatment. The aim of this cross-sectional national observational study was to assess the level of control (according to GINA guidelines) achieved in a group of asthmatics on omalizumab treatment, and to characterize the factors that influence the lack of control. We studied 306 asthmatics under omalizumab treatment for a median of 32 months (range 4-120). The level of control according to GINA was good in 25.2%, partial in 47.1% and poor in 24.5% of patients (data were missing for the remaining 3.2%). Comparison between…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyExacerbationCross-sectional studyOmalizumabOmalizumabComorbiditySettore MED/10 - Malattie Dell'Apparato RespiratorioExhaled nitric oxide; Exacerbations; Comorbidities; Asthma; Omalizumab; ControlSeverity of Illness IndexComorbiditiesExacerbationsExhaled nitric oxideInternal medicineSeverity of illnessControlMedicineAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsInflammation MediatorAsthmaRespiratory Function TestAgedCross-Sectional Studiebusiness.industryBiochemistry (medical)ExacerbationMiddle Agedmedicine.diseaseComorbidityAsthmaRespiratory Function TestsCross-Sectional StudiesItalyExhaled nitric oxidePhysical therapyObservational studyAsthma; Comorbidities; Control; Exacerbations; Exhaled nitric oxide; Omalizumab; Adult; Aged; Anti-Asthmatic Agents; Asthma; Comorbidity; Cross-Sectional Studies; Female; Humans; Inflammation Mediators; Italy; Male; Middle Aged; Omalizumab; Respiratory Function Tests; Severity of Illness Index; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)FemaleComorbiditieInflammation Mediatorsbusinessmedicine.drugHuman
researchProduct

ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle

2016

The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care p…

PediatricsAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; Rhinitis; Immunology and AllergyIMPACTHay feverRespiratory Medicine and AllergyDiseaseReview[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract0302 clinical medicineQUALITY-OF-LIFEHDE ALERHealth careMedicine and Health SciencesPERSISTENT ALLERGIC RHINITISMedicineImmunology and Allergy030212 general & internal medicine[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyAIRWAYS ICPComputingMilieux_MISCELLANEOUSRhinitiAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; RhinitisLungmedicin och allergiRhinitisPublic Health Global Health Social Medicine and Epidemiology3. Good healthREAL-LIFEAIRWAYS ICPsARIA; Rhinitis; ICT; EIP on AHA; Mobile technology; AIRWAYS ICPsHay feverCLINICAL-PRACTICE GUIDELINESHEALTHPulmonary and Respiratory Medicinemedicine.medical_specialtyEIP on AHAEUROPEAN INNOVATION PARTNERSHIPImmunologySocio-culturaleClinical decision support systemICT; EIP on AHAPredictive medicine03 medical and health sciencesQuality of life (healthcare)Mobile technologyJournal ArticleMobile technologyAsmaAsthmaScience & TechnologyARIAbusiness.industryAIRWAYS ICPs; ARIA; EIP on AHA; ICT; Mobile technology; Rhinitis;Settore MED/09 - MEDICINA INTERNAAIRWAYS-ICPSCorrectionmedicine.disease2008 UPDATEFebre del fencAsthmaFolkhälsovetenskap global hälsa socialmedicin och epidemiologi030228 respiratory systemFamily medicineICTVISUAL ANALOG SCALEbusiness
researchProduct

Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - G…

2016

International audience; Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role of the small airways in these diseases. Starting from an extensive literature review, both organizations developed, discussed, and approved the manifesto, which was subsequently approved and endorsed by the chairs of ARIA and GA2LEN. The manifesto describes the evidence gathered to date and defines and proposes issues on small airway involvement and management in asthma and COPD with the aim of challenging assumptions, fostering commitment, and bringin…

Allergic Rhinitislcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicineManifestomedicine.medical_specialtyAllergyChronic Obstructive Pulmonary DiseaseImmunologyMEDLINEDiseaseSettore MED/10 - Malattie Dell'Apparato Respiratoriosmall airways asthma aerosolBiochemistry03 medical and health sciences0302 clinical medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology/dk/atira/pure/subjectarea/asjc/2700/2723Position Article and GuidelinesmedicineImmunology and Allergy030212 general & internal medicinesmall airwayIntensive care medicineAsthmaCOPDLungbusiness.industryasthma airway inflammationOrganic Chemistrysmall airways asthma control aerosol1103 Clinical SciencesChronic Obstructive Pulmonary Disease Patientasthmarespiratory systemmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structure030228 respiratory systemPhysical therapylcsh:RC581-607AirwaybusinesscontrolThe World Allergy Organization Journal
researchProduct

The role of cefditoren in the treatment of lower community-acquired respiratory tract infections (LRTIs): from bacterial eradication to reduced lung …

2014

Lower respiratory tract infections (LRTIs), including pneumonia and acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD), are among the most common diagnoses in both outpatient and inpatient settings. Due to the burden of LRTIs healthcare providers must adopt practices focused on improving outcomes with the aim to reduce treatment failure and antibiotic resistances. Moreover, the role of acute and chronic infection in the pathogenesis of COPD has received considerable attention, since chronic infection can contribute to airways inflammation and COPD progression. This review discusses the role of cefditoren for the treatment of LRTIs, compared with the definition of "appropria…

Chronic ObstructiveDose-Response Relationship DrugDrug ResistanceBacterialMicrobial Sensitivity TestsPneumoniaSettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-Bacterial AgentsCephalosporinsCommunity-Acquired InfectionsDose-Response RelationshipPulmonary DiseasePulmonary Disease Chronic ObstructiveDrug Resistance Multiple BacterialPneumonia BacterialDisease ProgressionHumansAnti-Bacterial Agents; Cephalosporins; Community-Acquired Infections; Disease Eradication; Disease Progression; Dose-Response Relationship Drug; Drug Resistance Multiple Bacterial; Humans; Microbial Sensitivity Tests; Pneumonia Bacterial; Pulmonary Disease Chronic ObstructiveDisease EradicationDrugantibiotics outpatients COPDMultiple
researchProduct

Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study

2018

Abstract Background The query “are there animals at home?” is usually administered for collecting information on anamnesis. This modality to consider exposure to pet allergens constitutes a potential bias in epidemiological studies and in clinical practice. The aim of our study was to evaluate/quantify different modalities of exposure to cat/dog in inducing allergic sensitization. Methods Thirty Italian Allergy units participated in this study. Each centre was required to collect the data of at least 20 consecutive outpatients sensitized to cat/dog allergens. A standardized form reported all demographic data and a particular attention was paid in relieving possible modalities of exposure to…

lcsh:Immunologic diseases. AllergyAllergymedicine.medical_specialtyImmunologySettore MED/10 - Malattie Dell'Apparato RespiratorioPets exposureAllergic rhinitisAllergic sensitization03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologyAllergic rhinitiDogHypersensitivitymedicineImmunology and Allergy030212 general & internal medicineAllergic rhinitis Allergic sensitization Bronchial asthma Cat; Dog Hypersensitivity Pets Pets exposure Immunology and Allergy Immunology Molecular BiologyBronchial asthmaMolecular BiologyAllergic rhinitis; Allergic sensitization; Bronchial asthma; Cat; Dog; Hypersensitivity; Pets; Pets exposureAllergic sensitizationAnamnesisCATSModalitiesbusiness.industryResearchCatPetsmedicine.diseasePet ownershipPet030228 respiratory systemMulticenter studyAllergic rhinitis; Allergic sensitization; Bronchial asthma; Cat; Dog; Hypersensitivity; Pets; Pets exposure; Immunology and Allergy; Immunology; Molecular Biologylcsh:RC581-607businessClinical and Molecular Allergy
researchProduct

Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

2019

AIMS: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. METHODS: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. STAKEHOLDERS: Incl…

SENTINEL NETWORKAllergyRespiratory Medicine and AllergyReviewWORLD-HEALTH-ORGANIZATIONDiseaseRhinitis.App; Asthma; Care pathways; DG Santé; MASK; mHealth; Rhinitis0302 clinical medicineQUALITY-OF-LIFEPRECISION MEDICINEDG SantéHealth careMedicine and Health SciencesGRADING QUALITYImmunology and AllergyMedicinemHealthRinitisLungmedicin och allergiRhinitis0303 health sciencesThe MASK study groupPublic sectorApp ; Asthma ; Care pathways ; MASK ; mHealth ; Rhinitis ; DG SanteMOBILE TECHNOLOGY3. Good healthALLERGIC RHINITISCHRONIC RESPIRATORY-DISEASESRinitemHealthCare pathwaysEUROPEAN SYMPOSIUMCLINICAL-PRACTICE GUIDELINESLife Sciences & BiomedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMASKImmunologySettore MED/10 - Malattie Dell'Apparato RespiratorioPredictive medicine03 medical and health sciencesQuality of life (healthcare)App -MASKAsma030304 developmental biologyAsthmaARIAScience & TechnologyCare pathwaybusiness.industryChange managementCorrectionDG SanteRC581-607medicine.diseaseAsthma030228 respiratory systemApp; Asthma; Care pathways; DG Santé; MASK; mHealth; Rhinitis; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicineFamily medicineImmunologic diseases. AllergybusinessApp[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Bronchial thermoplasty in severe asthma: food for thoughts

2014

Asthma is a complex inflammatory disorder of the airways characterized by airway hyper-responsiveness and variable, reversible, airflow obstruction. Bronchial thermoplasty (BT) is a new modality for treating asthma. It targets airway smooth muscles (ASM) by delivering a controlled specific amount of thermal energy (radiofrequency ablation) to the airway wall through a dedicated catheter. The use of bronchial thermoplasty has been widely discussed for its potential in the treatment of asthma, since it seems to be able to reduce the symptoms of asthma. The definitive study for BT (AIR2 trial) employed a randomized, double-blind, sham-controlled design and enrolled 288 subjects with severe per…

InflammationSocio-culturaleTherapyasthma airflow obstruction treatmentSettore MED/10 - Malattie Dell'Apparato RespiratorioAsthma; Bronchial diseases; Inflammation.; TherapyAsthmaBronchial diseases
researchProduct

Building Bridges for Innovation in Ageing: Synergies between Action Groups of the EIP on AHA.

2017

The Strategic Implementation Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) proposed six Action Groups. After almost three years of activity, many achievements have been obtained through commitments or collaborative work of the Action Groups. However, they have often worked in silos and, consequently, synergies between Action Groups have been proposed to strengthen the triple win of the EIP on AHA. The paper presents the methodology and current status of the Task Force on EIP on AHA synergies. Synergies are in line with the Action Groups' new Renovated Action Plan (2016-2018) to ensure that their future objectives are coherent and fully connected. The …

AgingProcess managementGeriatrics & GerontologyEuropean Innovation Partnership on Active and Healthy Ageing polypharmacy education falls frailty integrated care citizen empowerment chronic respiratory diseasesHealth BehaviorChronic respiratory diseasesPARTNERSHIPCoaching[SHS]Humanities and Social Sciences0302 clinical medicineSurveys and Questionnaires80 and overMedicineCooperative BehaviorComputingMilieux_MISCELLANEOUSInterventionsmedia_commonintegrated careAged 80 and over:Enginyeria biomèdica [Àrees temàtiques de la UPC]Multiple Chronic ConditionOrganizational Innovation3. Good healthCHRONIC RESPIRATORY-DISEASESHealthAction planGeneral partnershipFallsHEALTHPartnershipINTERVENTIONSHumanmedia_common.quotation_subjectfallFrail ElderlyEuropean Continental Ancestry GroupBioengineeringWhite PeopleEducation03 medical and health sciencesEUROPEAN-UNIONActive and Healthy Ageingmedia_common.cataloged_instanceHumansBioenginyeriaEuropean unionAgedScience & TechnologyNutrition & DieteticsPreventionPREVENTIONCitizen empowerment030228 respiratory systemAction (philosophy)European Innovation Partnership on Active and Healthy Ageing; polypharmacy; education; falls; frailty; integrated care; citizen empowerment; chronic respiratory diseases; Accidental Falls; Aged; Aged 80 and over; Chronic Disease; Cooperative Behavior; Europe; Frail Elderly; Humans; Multiple Chronic Conditions; Organizational Innovation; Polypharmacy; Surveys and Questionnaires; Aging; European Continental Ancestry Group; Health BehaviorGeriatrics and GerontologyGerontologySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]OPERATIONAL DEFINITIONEMPOWERMENTMedicine (miscellaneous)Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyChronic respiratory-diseasesAllergic rhinitisQUALITY-OF-LIFEEuropean-UnionNutrition and DieteticSurveys and Questionnaire030212 general & internal medicineMultiple Chronic ConditionsEmpowermenteducationNutrition and DieteticsFrailtyAccidental FallIntegrated careALLERGIC RHINITISEuropeSettore MED/42EmpowermentLife Sciences & BiomedicinefrailtyEuropean Innovation Partnership on Active and Healthy AgeingJournal ArticleMETIS-318216IR-101708Responsible Research and Innovationbusiness.industrychronic respiratory diseaseIntegrated careOperational definition3121 General medicine internal medicine and other clinical medicineChronic DiseasePolypharmacycitizen empowermentAccidental Fallschronic respiratory diseases; citizen empowerment; education; European Innovation Partnership on Active and Healthy Ageing; falls; frailty; integrated care; polypharmacy; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and GerontologyQuality-of-lifebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe journal of nutrition, healthaging
researchProduct

Pulmonary hypertension in COPD and lung transplantation: Timing and procedures

2014

The prevalence of pulmonary hypertension (PH) in the general chronic obstructive pulmonary disease (COPD) population is undefined because stable COPD patients do not routinely undergo screening echocardiogram and right heart catheterization. Most studies published on this topic are focused on a highly selected group of patients with moderate to severe disease awaiting lung transplantation, since hemodynamic data from cardiac catheterization are part of the standard transplant evaluation. In a very recent article, Hurdman et al. studied the characteristics and outcomes, with a particular focus on mortality, of extensively phenotyped, consecutive patients with PH-COPD over a 9-year period. Th…

Emphysema; Hypertension; Lung diseases; Lung transplantation; Obstructive; Pulmonary; Respiratory function testsEmphysemaLung transplantationObstructiveHypertensiontransplantation COPD pulmonary hypertensionPulmonarySettore MED/10 - Malattie Dell'Apparato RespiratorioRespiratory function testsLung diseases
researchProduct

Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

2021

n/a

Caratmedicine.medical_specialtybusiness.industryMEDLINESettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.diseaseRhinitis AllergicAsthmaTest (assessment)Internal medicineHumansImmunology and AllergyMedicinebusinessRhinitisAsthmaThe Journal of Allergy and Clinical Immunology: In Practice
researchProduct